Latest News Releases Keyword Search Year All2026202520242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996 8/12/26 Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia 8/7/26 Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist 7/30/26 Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results 7/23/26 Neurocrine Biosciences Announces Key Leadership Hiring, Promotions 7/21/26 Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer 7/9/26 Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results Resources Email Alerts 2025 Annual Report 2026 Proxy Statement Webcasts & Presentations
8/12/26 Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
8/7/26 Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
7/9/26 Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results